Sialadenitis and xerostomia also exhibit class-specific patterns: toxicities are more pronounced with anti-CTLA-4 agents and combination therapy (ZhangT et al., 2022), though our data identified nivolumab (anti-PD-1) as a key associated agent. Here, CTLA4 is linked to sialadenitis.